New data boosts Novo against Sanofi in insulin-market fight

Novo Nordisk ($NVO) has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba--and win it points against heavyweight rival Sanofi ($SNY). In a recent study, the med hit its primary endpoint, cutting the number of hypoglycemic events by 30% compared with the French drugmaker's Lantus. Tresiba's rate of hypoglycemia tallied 186 events per 100 patient years, compared with 265 on Lantus. And as for hypoglycemia episodes at night, the study's secondary endpoint, Tresiba slashed them by 42%. More from FiercePharmaMarketing

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.